@article {Sakas2022.01.25.22269847, author = {Zoe Sakas and Kyra A. Hester and Katie Rodriguez and Saly Amos Diatta and Anna S. Ellis and Daouda Malick Gueye and Dawn Matapano and Pr Souleymane Mboup and Emily Awino Ogutu and Chenmua Yang and Robert A. Bednarczyk and Matthew C. Freeman and Moussa Sarr and the Vaccine Exemplars Research Consortium}, editor = {Bueno, Natalia and Zunino, Francisco Castillo and Darwar, Roopa and Dounebaine, Bonheur and Dudgeon, Matthew R. and Escoffery, Cam and Isett, Kimberley R. and Jaishwal, Chandni and James, Hanleigh and Keskinocak, Pinar and Montagnes, B. Pablo and Nazzali, Dima and Orenstein, Walter and Robayo, Miguel Rueda and Rosenblum, Simone and Smalley, Hannah K.}, title = {Critical success factors for high routine immunization performance: A case study of Senegal}, elocation-id = {2022.01.25.22269847}, year = {2022}, doi = {10.1101/2022.01.25.22269847}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {BACKGROUND The essential components of a vaccine delivery system are well-documented, but robust evidence is lacking on how policies and implementation strategies are operationalized to drive catalytic improvements in coverage. To address this gap, we identified success factors that supported improvements in routine immunization coverage in Senegal, especially from 2000 to 2019.METHODS We identified Senegal as an exemplar in the delivery of childhood vaccines through analysis of DTP1 and DTP3 coverage data. Through interviews and focus group discussions at the national, regional, district, health facility, and community-level, we investigated factors that contributed to high and sustained vaccination coverage. We conducted a thematic analysis through application of implementation science frameworks to determine critical success factors. We triangulated these findings with quantitative analyses using publicly available data.RESULTS The following success factors emerged: 1) Strong political will and prioritization of resources for immunization programming supported urgent allocation of funding and supplies; 2) Collaboration between the Ministry of Health and Social Action and external partners fostered innovation, capacity building, and efficiency; 3) Improved surveillance, monitoring, and evaluation allowed for timely and evidence-based decision making; 4) Community ownership of vaccine service delivery supported tailored programming and quick response to local needs; and 5) Community health workers spearheaded vaccine promotion and demand generation for vaccines.CONCLUSION The vaccination program in Senegal was supported by evidence-based decision making at the national-level, alignment of priorities between governmental entities and external partners, and strong community engagement initiatives that fostered local ownership of vaccine delivery and uptake. High routine immunization coverage was likely driven by prioritization of immunization programming, improved surveillance systems, a mature and reliable community health worker program, and tailored strategies for addressing geographical, social, and cultural barriers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill \& Melinda Gates Foundation, Seattle, WA (OPP1195041) with a planning grant from Gates Ventures, LLC, Kirkland, WA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the National Ethical Committee for Health Research (CERNS, Comite National d Ethique pour la Recherche en Sante) in Dakar, Senegal (00000174). This study was also approved as exempt human research by the Institutional Review Board committee of Emory University, Atlanta, Georgia, USA (IRB00111474). All participants provided written consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not publicly available as all data are confidential. Data may be available upon request.}, URL = {https://www.medrxiv.org/content/early/2022/01/28/2022.01.25.22269847}, eprint = {https://www.medrxiv.org/content/early/2022/01/28/2022.01.25.22269847.full.pdf}, journal = {medRxiv} }